A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

Clinical trial NCT05828303 · WITHDRAWN

Trial details

NCT number: NCT05828303
Sponsor: Turning Point Therapeutics, Inc.
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor Metastatic Solid Tumor

Start date: 2024-11-15
Primary completion: 2025-07-31
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.